Zafgen Inc (NASDAQ:ZFGN) insider Thomas E. Hughes sold 32,000 shares of the stock in a transaction dated Thursday, June 28th. The shares were sold at an average price of $10.00, for a total transaction of $320,000.00. Following the completion of the transaction, the insider now owns 125,247 shares of the company’s stock, valued at approximately $1,252,470. The sale was disclosed in a filing with the SEC, which can be accessed through this link.
Shares of Zafgen opened at $9.55 on Tuesday, according to MarketBeat Ratings. The stock has a market capitalization of $281.97 million, a P/E ratio of -5.03 and a beta of -0.58. The company has a debt-to-equity ratio of 0.31, a current ratio of 12.27 and a quick ratio of 12.27. Zafgen Inc has a 52-week low of $3.21 and a 52-week high of $10.25.
Zafgen (NASDAQ:ZFGN) last announced its earnings results on Tuesday, May 8th. The biopharmaceutical company reported ($0.58) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.52) by ($0.06). equities research analysts expect that Zafgen Inc will post -2.5 EPS for the current fiscal year.
Large investors have recently bought and sold shares of the company. A.R.T. Advisors LLC boosted its holdings in shares of Zafgen by 62.9% in the first quarter. A.R.T. Advisors LLC now owns 23,053 shares of the biopharmaceutical company’s stock worth $171,000 after buying an additional 8,904 shares during the period. Northern Trust Corp boosted its holdings in shares of Zafgen by 25.2% in the first quarter. Northern Trust Corp now owns 61,257 shares of the biopharmaceutical company’s stock worth $456,000 after buying an additional 12,348 shares during the period. Barclays PLC boosted its holdings in shares of Zafgen by 139,086.7% in the first quarter. Barclays PLC now owns 20,878 shares of the biopharmaceutical company’s stock worth $155,000 after buying an additional 20,863 shares during the period. Element Capital Management LLC acquired a new position in shares of Zafgen in the first quarter worth about $174,000. Finally, Algert Global LLC acquired a new position in shares of Zafgen in the first quarter worth about $195,000. Institutional investors own 57.36% of the company’s stock.
A number of equities analysts recently issued reports on ZFGN shares. Zacks Investment Research upgraded shares of Zafgen from a “hold” rating to a “buy” rating and set a $9.00 target price for the company in a research report on Wednesday, March 7th. ValuEngine upgraded shares of Zafgen from a “hold” rating to a “buy” rating in a research report on Tuesday, June 26th. Cowen reiterated a “hold” rating on shares of Zafgen in a research report on Monday, June 25th. Finally, JMP Securities reiterated an “outperform” rating and issued a $20.00 target price (up previously from $11.00) on shares of Zafgen in a research report on Wednesday, March 7th.
Zafgen Company Profile
Zafgen, Inc, a clinical-stage biopharmaceutical company, develops therapies for patients suffering from metabolic diseases comprising type 2 diabetes, Prader-Willi syndrome (PWS), and other metabolically related disorders. The company's lead product candidate is ZGN-1061, a fumagillin-class methionine aminopeptidase 2 (MetAP2) inhibitor administered by subcutaneous injection, which is in Phase 2 clinical trial and profiled for its utility in the treatment of type 2 diabetes and other related metabolic disorders.
Receive News & Ratings for Zafgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zafgen and related companies with MarketBeat.com's FREE daily email newsletter.